Evidence map›Paper›PMID 32363929›Full record

Trial reportFuture oncology (London, England)2020

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.

Danielle A Murphy, Brian I Rini, Bernard Escudier, Robert J Motzer, Panpan Wang, Sherry Li, J Andrew Williams, Jamal C Tarazi, Jean-Francois Martini

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Danielle A MurphyPfizer Oncology, San Diego, CA 92121, USA.
Brian I RiniDepartment of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA.
Bernard EscudierDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Robert J MotzerDepartment of Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Panpan WangPfizer Oncology, Shanghai, China.
Sherry LiPfizer Oncology, San Diego, CA 92121, USA.
J Andrew WilliamsPfizer Oncology, San Diego, CA 92121, USA.
Jamal C TaraziPfizer Oncology, San Diego, CA 92121, USA.
Jean-Francois MartiniPfizer Oncology, San Diego, CA 92121, USA.
Pfizer (United States) · USCleveland Clinic · USInstitut Gustave Roussy · FRMemorial Sloan Kettering Cancer Center · USPfizer (China) · CN

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiomarkersAxitinibCarcinoma, Renal CellFemaleGene ExpressionGene Expression ProfilingHumansImmunomodulationKaplan-Meier EstimateKidney NeoplasmsLymphocytes, Tumor-InfiltratingMaleMicroRNAsNeovascularization, PathologicProtein Kinase InhibitorsAxitinibBiomarkersMicroRNAsProtein Kinase Inhibitorsaxitinibbiomarkerrenal cell carcinomasorafenibsurvivaltumor response

Identifiers

PMID32363929
PMCPMC8459336
OpenAlexW3022126605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.